NCT06408311Active, not recruitingPhase 1
Safety of ENC-201-CED ENCRT
A Safety and Tolerability Study of ENC=201-CED in Participants With Type 1 Diabetes Receiving Islet Infusion
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a subcutaneous space in patients with Type I diabetes.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 2 May 2024
- Start date
- 1 May 2024
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Encellin
- Diseases
- Type 1 diabetes
- NCT number
- NCT06408311
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- From 1 May 2024 to the primary completion date, 31 Jul 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Candidates are excluded based on the site's criteria for standard of care islet infusion.
Who the study is looking for
- Candidates must satisfy site's eligibility for standard of care islet infusion.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McGill University Health Centre Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| UHN Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.